Pharmacotherapy of Autism Spectrum Disorders

Dr. Blankenship is Professor of Psychiatry, Indiana University, 3171 N Meridian St; Indianapolis, IN 46208; E-mail: [email protected]. The author and staff in a position to control the content of this CME activity have disclosed that they and their spouses/life partners (if any) have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity. Dr. Blankenship has disclosed that only aripiprazole and risperidone have been approved by the U.S. Food and Drug Administration for treatment of irritability associated with autistic disorder in children and adolescents, and that use of other medications discussed in this article is considered “off-label.” Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on October 31, 2012.